Lemborexant (Dayvigo) for the Treatment of Insomnia

Rhodes, Morgan Adams PharmD, BCACP

University of South Carolina School of Medicine, Columbia, South Carolina

Address correspondence to Morgan Adams Rhodes, PharmD, BCACP, at [email protected]. Reprints are not available from the author.

Author disclosure: No relevant financial affiliations.

American Family Physician 103(4):p 241-242, February 15, 2021.

Lemborexant (Dayvigo) is labeled for the treatment of insomnia to improve sleep onset and maintenance in adults. It is the second dual orexin receptor antagonist and blocks wake-promotion by blocking the binding of neuropeptides, orexin A, and orexin B. Lemborexant is a Schedule IV controlled substance.